---
schema_version: "secwatch.filing_event.v1"
accession: "0001448431-26-000014"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2026-08-12T20:07:41+00:00"
generated_at: "2026-08-12T20:09:30.605084+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q2 revenue falls 30% to $20.5M, swings to GAAP net loss; reaffirms FY guidance

## Summary
- Q2 revenue $20.5M, down 30% YoY from $29.2M; GAAP net loss $(0.7)M or $(0.04)/share vs $1.5M net income ($0.08) in Q2 2025.
- Non-GAAP net income $3.1M ($0.16 diluted) vs $3.7M ($0.19) prior year; adjusted EBITDA $4.9M vs $5.8M.
- FY2026 guidance reaffirmed: revenue $95-100M and adjusted EBITDA $21-25M.
- CFO Ed Stelmakh steps down Dec 31, 2026; Andy D'Silva becomes CFO and Heather Favazza CAO effective Jan 1, 2027.
- Stelmakh gets 12 months base salary ($450K/yr), $247.5K bonus lump sum, COBRA; advisory role through Dec 2027.

## SEC filing metadata
- accession: 0001448431-26-000014
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2026-08-12T20:07:41+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000144843126000014/0001448431-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000144843126000014/oprx-20260807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001448431-26-000014
- JSON: https://secwatch.observer/filing/0001448431-26-000014.json
- Plain text: https://secwatch.observer/filing/0001448431-26-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.